P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

• C. Ryan,
• D. Brander,
• P. Barr,
• S. Tyekucheva,
• Y. Ren,
• L. Hackett,
• M. McDonough,
• K. Pena Del Aguila,
• M. McEwan,
• M. Collins,
• J. Abramson,
• E. Jacobsen,
• A. LaCasce,
• D. Fisher,
• J. Brown,
• M. Davids

Affiliations

C. Ryan

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

D. Brander

2 Duke University Cancer Center, Durham

P. Barr

3 University of Rochester Wilmot Cancer Institute, Rochester

S. Tyekucheva

4 Data Science, Dana-Farber Cancer Institute, Boston, United States of America

Y. Ren

4 Data Science, Dana-Farber Cancer Institute, Boston, United States of America

L. Hackett

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

M. McDonough

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

K. Pena Del Aguila

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

M. McEwan

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

M. Collins

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

J. Abramson

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

E. Jacobsen

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

A. LaCasce

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

D. Fisher

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

J. Brown

1 Medical Oncology, Dana-Farber Cancer Institute, Boston

M. Davids

1 Medical Oncology, Dana-Farber Cancer Institute, Boston